Company ProfilePremium

Daeyu Co., Ltd.

Company Profile Analysis

Ticker: 290380.KQ주식회사 대유

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daeyu Co., Ltd. - Company showcase

Year Founded & Workforce

1977

161 Employees

Daeyu Co., Ltd. logo

Daeyu Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daeyu Co., Ltd. Overview

Daeyu is a 49-year-old Korean specialty agri-inputs manufacturer. Its franchise was built on foliar-applied (leaf-spray) specialty fertilizers. Its flagship, Nargen (나르겐), launched in 1978, is described by the company as Korea's first foliar-application Class-4 compound fertilizer. The company has since broadened into certified organic agricultural materials, a modest crop-protection (pesticide) line, plant-growth regulators and quasi-drugs for livestock use. It sells mainly through Korea's dense network of independent agro-chemical and seed retailers (about 72% of Q1 FY2025 sales) and through NongHyup (about 27%). Annual revenue is roughly KRW 34bn, and it has stayed between KRW 30bn and 36bn every year from FY2020 to FY2025. Operating margins have typically been high single digits to high teens. Between 2020 and 2025, however, its corporate story was dominated by ownership and governance events rather than operations. A leveraged change of control in 2020 was followed by a circular cross-shareholding with Jogwang ILI and Andiforce, the 2023 indictment of then-CEO Kim Woo-dong, three consecutive years of net losses, and delisting in 2025. Since delisting, Daeyu has operated as a privately traded, Jogwang ILI-controlled company. Competitors Chobi and Kyungnong hold a contested 18% minority block.


Company's own description. In its filings, Daeyu describes itself as a company founded in Gyeongsan in April 1977 whose main business is manufacturing and selling fertilizers and pesticides, together with manufacturing, importing and selling quasi-drugs (shareholder meeting notice, KIND, Nov 2024). The same document says Daeyu maintains a high share in Class-4 foliar compound fertilizers, built on infrastructure developed over 48 years. It says the company is using its sales network to expand newer lines such as pesticides. Management attributes recent revenue softness to temporary competitive intensity and a slowing market. It expects growth to resume as pesticide consumption declines structurally and demand for eco-friendly organic materials rises, and it describes itself as the number-one eco-friendly specialty-fertilizer supplier. The Q1 FY2025 quarterly report (KIND, 15 May 2025) repeats this outlook and attributes the 2025 dip to an economic slump and regional disasters such as wildfires.

The NICE registry lists Daeyu's business purposes as manufacturing Class-4 compound fertilizer and pesticides, wholesale and retail, e-commerce, quasi-drug manufacturing, and leasing of non-residential buildings (Saramin/Jobkorea). Its manufacturing licences cover Class-4, Class-3 and Class-1 compound fertilizers, micronutrient fertilizers, lime and magnesia fertilizers, organic fertilizers, eco-friendly organic materials, other fertilizers and crop protection agents (company profile via Saramin).

Business model. Daeyu is predominantly a branded product manufacturer. It earns revenue from the sale of manufactured goods (제품) and traded or imported goods (상품). Imported products have included Dutch-origin specialty fertilizers such as the Fertigro line (Etoday, Aug 2021). There is no material subscription, service or licensing revenue. The building-leasing purpose suggests minor rental income from its Seoul headquarters building, but the amount is not disclosed.

Value-chain position. Daeyu sits at the formulation and branding stage. It buys raw nutrients, active ingredients, natural extracts and microbial strains, then formulates them into liquid, powder, granular and, since 2021, high-concentration gel-fluid products. It sells to distributors that serve farmers. It does not produce commodity nitrogen, phosphate or potash; those are dominated in Korea by Namhae Chemical and similar producers. Its value lies in formulation know-how, product registrations (fertilizer, organic-material and pesticide registrations), test-laboratory designations, and farmer-facing brand recognition.

Customer types and channels. The Q1 FY2025 quarterly report (KIND) shows three domestic channels:

The end-customers are Korean farmers, concentrated in horticulture (fruit trees, vegetables, protected cultivation), rice and specialty crops. Smaller segments include home gardening (the "MyFarming" kit launched May 2022), tree and landscape care (a stated development priority in 2021), livestock (quasi-drugs and livestock-housing materials listed on the company website) and, from 2019, aerial and wide-area application through 14 products designed for drone or aircraft spraying (company history).

End-markets. These are Korean specialty and foliar fertilizers, certified organic agricultural materials (유기농업자재), crop protection (notably plant growth regulators such as gibberellin and insecticides such as abamectin products), and a small, early-stage export business (Thailand, Japan, Mongolia, Kazakhstan, Egypt).

Independent characterization. Daeyu is a niche, cash-generative specialty formulator with a strong rural brand and a retailer-heavy distribution model. Its scale is small (about KRW 34bn revenue) and its growth has been flat for six years. The operating business appears to have been reasonably resilient through the governance crisis: operating income was positive in four of the last five years and recovered to KRW 2.8bn in FY2025. The equity story, however, was impaired by non-core investments made at the parent's direction, most prominently the Andiforce stake, and by the governance failures that led to delisting. The key analytical tension is a sound, if small, operating franchise held inside a contested and opaque ownership structure.

Strategy

Stated strategic themes (management statements in filings and releases).

  1. Eco-friendly shift. Management expects structural decline in pesticide consumption and growth in certified organic materials. It positions Daeyu as the leading eco-friendly specialty-fertilizer player and stresses differentiated eco-friendly fertilizers and pesticides (KIND shareholder notice, Nov 2024; Q1 FY2025 report).

  2. Pesticide line extension through the existing retailer network (KIND, Nov 2024).

  3. Export diversification into Thailand, Japan, Mongolia, Kazakhstan and Egypt, alongside domestic government-subsidy programmes (Edaily, Aug 2024; company history).

  4. Manufacturing modernization. The automated Goesan Smart Campus is meant to lower costs and improve efficiency (Edaily, Aug 2024).

  5. New product development. Priorities include high-concentration gel fluids, pesticide range expansion, tree-care products and organic materials (Etoday, Aug 2021), and more recently neem-based pest management (Nongmin, Jan 2025).

  6. Digital marketing through YouTube (Daeyu-man channel) and online retail (Etoday, Aug 2021; company history).

Initiatives in the last 24 months (Oct 2024 – Oct 2026).

Medium-term financial targets and guidance. None are publicly disclosed. The only stated orientation is a qualitative expectation that revenue will return to growth. In 2018, the then-CEO described the specialty-fertilizer niche as part of a domestic fertilizer market of about KRW 3tn (Etoday, Jul 2018).

Cost programmes. The "diet management" declaration (January 2021) is the only named cost programme. SG&A and one-off costs fell 11.0% in H1 FY2024 (Edaily, Aug 2024). No quantified targets are disclosed.

ESG commitments. No public emissions or sustainability targets.

Products & Services

Portfolio breadth. At its 2018 IPO, Daeyu reported about 1,500 fertilizer products, 43 pesticide products and 56 organic agricultural material products (Etoday, Jul 2018). In 2021 it cited about 1,200 items (Etoday, Aug 2021). In 2020 it cited about 70 specialty-fertilizer products and claimed the number-one share in foliar fertilizers, including Class-4 compound fertilizers (Wonyesanup, Sep 2020). The website organizes products into five categories: Fertilizers, Organic Agricultural Materials, Crop Protection, Quasi-drugs, and Livestock-housing Materials. Pricing is not publicly disclosed for any product.

Fertilizers (foliar and specialty compound fertilizers)

Product / lineDescription and capabilityTarget customerLaunch / latestNotes
Nargen (나르겐) and derivatives (Super Nargen, New Nargen, Double Nargen)Foliar Class-4 compound fertilizer; credited with reviving a protected pine in 1980Horticulture and fruit growers; tree care1978 (original)Flagship; +16.3% in H1 2021
Mirigeun (미리근) / Mirigeun AlphaRoot-promotion fertilizer lineVegetable and fruit growers—Named core line (NICE 2026)
Burio (부리오) / Burio GoldSpecialty compound fertilizer lineHorticulture—Named core line (NICE 2026)
Calcium and micronutrient range (e.g., Daeyu Calcium 100, Fast Calcium 23, Boron, Selenium, Germanium products)Correction of deficiencies and physiological disordersFruit and vegetable growersVariousListed in website product keywords
Fruit-sizing and colouring fertilizersFruit enlargement, colour promotion, ripeningOrchardsPatents from 2005–2006Patents on colour-promotion and selenium compound fertilizers
High-Enriched Gel Fluid formulationNew high-concentration gel-fluid fertilizer formatGrowers seeking efficient applicationJan 2021Gel products exported to Thailand from Aug 2024
Aerial and wide-area application range (14 products)Fertilizers and organic materials formulated for aerial or drone sprayingRice and field-crop growers; co-opsJun 2019Company called it a domestic first
MyFarming (마이파밍)Home-gardening plant-nutrient setConsumersMay 2022B2C extension
Imported specialty fertilizers (e.g., Fertigro (퍼트그로))Dutch-origin specialty fertilizersGrowers—+81.2% in H1 2021

Organic Agricultural Materials (certified eco-friendly inputs)

Product / lineDescriptionLaunch / latestNotes
Daeyu Nargen OrganicNatural-extract organic agricultural materialMar 2017Certified eco-friendly material
Chongjinssak (총진싹) seriesOrganic pest-management material—+664.8% in H1 2021
Mulpure (물푸레) seriesOrganic material series—+271.0% in H1 2021
Neem-extract pest-management productPest management based on neem (subtropical plant) extract2025 (announced)Nongmin, Jan 2025
Super Kelp (슈퍼켈프)Seaweed-based organic materialExported to Egypt Jan 2026Company history
Richen Fulvic (리첸풀빅)Fulvic-acid organic materialExported to Kazakhstan Feb 2026Company history
Chitosan liquid (대유키토산액제)Eco-friendly chitosan product2,002Full production supplied to NongHyup in 2002
Hoechunto (회춘토) granulesEco-friendly soil materialAug 2003Company history
Garujaba (가루자바)Product to reduce powdery mildew and grey mould damageDec 2003Company history
Plant-oil formulations (One-Stop, One-Shot 51)Eco-friendly plant-oil formulationsJan 2003Company history
Soil conditionersExported to Japan2024–2025Company history

The company claimed the largest number of organic-material registrations in Korea (Nongupin, 2018).

Crop Protection (pesticides and plant growth regulators)

ProductDescriptionNotes
Gibberellin (지베레린) products, including a paste formulation with visual application markingPlant growth regulatorPatent filing on a marked gibberellin paste (application no. 10-2017-0027264)
Abamec-kill (아바멕킬)Abamectin-based insecticide/acaricideNamed core crop-protection line (NICE 2026)
Ethephon liquid (에렐폰액제)Growth regulatorProduced from Mar 2003
Zinc-lime Bordeaux wettable powderFungicidePatent registered Jan 2008
Microbial pesticides (e.g., 불로토, 회춘토 water-soluble formulations; Dr. Plant (닥터푸란트), Soil 0119, Chanchanchan liquid formulations)Microbial control agentsProduced from 2000
Pollination aid / fruit-thinning spraysPatented compositions (pollen-removal spray, Sep 2018)Company history

Quasi-drugs and Livestock-housing Materials

Daeyu registered quasi-drug manufacturing in December 2011. Its website lists quasi-drug and livestock-housing material categories, and filings refer to "animal quasi-drugs." Individual products, specifications and revenue are not publicly disclosed. Quarantine and disinfection products were described as under development in 2018 (Nongupin).

Digital and Direct Channels

The company runs a Naver SmartStore online shop, a Naver blog, and the YouTube channel "Daeyu-man" (대유맨), which passed 100,000 subscribers in November 2025 (company history). Management stated in 2021 that it would use YouTube to drive sales (Etoday, Aug 2021).

Financial Narrative

Income Statement

FY2022 net income is KRW -17.6bn per FnGuide and KRW -17.94bn per NICE; the discrepancy is noted. FY2025 pre-tax income was KRW 0.64bn, and a tax benefit of KRW 0.35bn lifted net income to KRW 0.98bn (NICE via Jobkorea).

Margins and Growth (%)

Revenue CAGR. FY2021–FY2025: about -1.9% per year (36.3 to 33.7). FY2020–FY2025: about 0.0% (33.6 to 33.7). In effect, revenue has gone nowhere for six years.

Balance Sheet: notes and sources

Source: FnGuide (FY2022–FY2024) and NICE via Jobkorea (FY2025). FY2025 borrowings are derived from NICE's borrowings-to-assets ratio of 15.41% applied to total assets; this is an approximation. Cash and equivalents, the short/long-term debt split, goodwill and intangibles are not publicly disclosed. Total assets were KRW 94.37bn in 2020 (Wikipedia KO). Property, plant and equipment (land and buildings) had a book value of KRW 36.3bn at 30 June 2025 (Hankyung Market Insight, Aug 2025).

Cash Flow

FY2025 operating cash flow was KRW 6.33bn. Investing cash flow was a net inflow of KRW 4.72bn, the source of which is not disclosed. NICE also reports "cash operating income" of KRW 7.01bn (all NICE via Jobkorea). Capital-raising and outflow events: the KRW 34bn rights offering (Feb 2022) and the early redemption of the KRW 7.0bn second-series CB (Jun 2023).

Ratios

ROE and ROA for FY2023–FY2024 are computed on average balances. FnGuide reports FY2024 ROE of -10.12%, consistent with the computed figure. FY2025 ratios are from NICE via Jobkorea or computed from its figures. ROIC (1.04%, NICE) is not tabulated separately. Net debt/EBITDA cannot be computed because EBITDA and cash are not disclosed. A partial cash-conversion estimate gives about 27 days of receivables and about 121 days of inventory; payables days are not disclosed, so the full cash conversion cycle cannot be computed.

Interim Data Points

Q1 FY2025 revenue is shown as KRW 10.1bn by FnGuide and as KRW 10.6bn by the sum of the KIND channel table; the discrepancy is noted. Q1 FY2025 gross profit was KRW 5.01bn versus KRW 5.13bn a year earlier, and OP was KRW 1.45bn versus KRW 2.03bn (KIND).

Commentary on Trends, Inflections and Drivers

Revenue: a flat franchise with sharp seasonality. Revenue has stayed in a KRW 30–36bn band since FY2020. The FY2023 dip (-13.8%) coincided with the trading suspension, the indictment and an emergency management structure. Management attributed it to temporary competitive intensity and a weak market. FY2024 recovered 11.1%, led by fertilizer and organic materials (+10.6% for 9M) and pesticides and animal quasi-drugs (+10.8%). FY2025 was flat (-0.8%), and the company cited economic weakness and regional disasters such as wildfires. Seasonality is extreme. Q4 FY2024 revenue was only KRW 1.8bn against KRW 9.6bn in Q3, which is consistent with the filing's statement that pesticide sales run from pre-season preparation (February) through harvest (September).

Operating profitability: from high-teens margin to high single digits. The FY2021 margin of 17.6% followed the 2021 "diet management" cost programme and record H1 sales. The H1 FY2021 margin of 35.5% was offset by an H2 operating loss of about KRW 2.2bn, implying heavy Q4 cost absorption. Margins compressed in FY2022 (12.7%), turned negative in FY2023 (-1.8%) and recovered to 6.6% in FY2024 and 8.4% in FY2025. Management credits the recovery to SG&A cuts (one-off and SG&A expenses down 11.0% in H1 FY2024) and efficiency gains at the Goesan plant, which entered full operation in early 2024 (Edaily, Aug 2024). The FY2025 gross margin of about 49% indicates strong pricing power at the formulation level. Operating expenses of about KRW 13.6bn (gross profit less OP) absorb most of it. For a KRW 34bn business, that SG&A load is heavy and reflects the field-sales-driven retailer model.

The below-the-line problem. The defining feature of FY2022–FY2024 is the gap between operating results (positive in FY2022 and FY2024) and net results (cumulative net losses of about KRW 47.7bn over three years). The sources do not itemize these losses. The pattern is consistent with valuation losses and impairments on non-operating investments, of which the Andiforce stake is the most significant known exposure. Prosecutors alleged that Daeyu paid about KRW 6.5bn for a partnership interest holding Andiforce shares that later fell to about KRW 4.4bn (Hankyung, Jan 2026). Andiforce itself recorded large valuation losses on its biotech investments (Dealsite, Apr 2025). This attribution is an analytical inference, not a disclosed breakdown.

Balance sheet: deleveraged and equity-heavy, but shrunk. Total assets fell from KRW 142.4bn (FY2022) to KRW 95.2bn (FY2025), and equity fell from KRW 106.5bn to KRW 77.0bn. Liabilities halved from KRW 35.8bn to KRW 18.1bn, helped by the June 2023 early redemption of the KRW 7.0bn CB. The equity ratio of 81% and current ratio of 2.08x indicate low financial risk. The FY2022 balance sheet had been inflated by the February 2022 KRW 34bn rights offering. Part of that cash went into the Goesan plant (about KRW 19bn earmarked); the rest is not traceable in the sources reviewed.

Returns. On FY2025 average equity of about KRW 76.5bn, ROE was 1.3%. An operating business producing KRW 2.8bn of OP on KRW 77bn of book equity earns a low return on capital. This reflects a capital base swollen by the 2022 raise, idle or non-core assets (Andiforce stake, Seoul real estate), and the new plant's still-modest throughput.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Fertilizer & agro-materials segment revenue (KRW Bn)

36.335.430.533.933.7

Segment operating income (KRW Bn)

6.44.5-0.52.22.8

Segment operating margin (%)

17.612.7-1.86.68.4

Segment revenue YoY growth (%)

8.0-2.5-13.811.1-0.8

Share of total revenue (%)

100100100100100

Product Category Details

Product categoryDisclosed mix / growthPeriodSource

Fertilizers & organic materials (Nargen, Mirigeun, Burio series)

85–87% of revenue

2026 interim periods

NICE via Jobkorea

Crop protection (gibberellin, Abamec-kill)

12–14% of revenue

2026 interim periods

NICE via Jobkorea

Fertilizers & organic materials

+9.0% YoY

H1 FY2024

Edaily, Aug 2024

Pesticides

+11.2% YoY

H1 FY2024

Edaily, Aug 2024

Animal quasi-drugs

+4.4% YoY

H1 FY2024

Edaily, Aug 2024

Fertilizers & organic materials

+10.6% YoY

9M FY2024

Company release (Financial News), Nov 2024

Pesticides & animal quasi-drugs

+10.8% YoY

9M FY2024

Company release, Nov 2024

Nargen series

+16.3% YoY

H1 FY2021

Etoday, Aug 2021

Mirigeun series

+14.2% YoY

H1 FY2021

Etoday, Aug 2021

Burio series

+5.5% YoY

H1 FY2021

Etoday, Aug 2021

Dutch-origin imports (Fertigro etc.)

+81.2% YoY

H1 FY2021

Etoday, Aug 2021

Chongjinssak (총진싹) organic pest-management series

+664.8% YoY

H1 FY2021

Etoday, Aug 2021

Mulpure (물푸레) organic series

+271.0% YoY

H1 FY2021

Etoday, Aug 2021

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

36.335.430.533.933.7

Gross profit (KRW Bn)

————16.4

Operating income (KRW Bn)

6.44.5-0.52.22.8

Pre-tax income (KRW Bn)

————0.6

Net income (KRW Bn)

—-17.6-22.0-8.11.0

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

————48.7

Operating margin (%)

17.612.7-1.86.68.4

Net margin (%)

—-49.7-72.1-23.92.9

Revenue growth YoY (%)

8.0-2.5-13.811.1-0.8

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

142.4106.894.195.2

Current assets (KRW Bn)

———35.7

Non-current assets (KRW Bn)

———59.5

Total liabilities (KRW Bn)

35.822.518.118.1

Current liabilities (KRW Bn)

———17.1

Total equity (KRW Bn)

106.584.376.077.0

Paid-in capital (KRW Bn)

12.412.412.412.4

Working capital (KRW Bn)

———18.5

Total debt / borrowings (KRW Bn, derived)

———14.7

Cash Flow

MetricFY2025

Operating cash flow (KRW Bn)

6.3

Investing cash flow (KRW Bn)

4.7

Margin Analysis (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE (%)

—-23.1-10.11.3

ROA (%)

—-17.7-8.11.0

Liabilities to equity (%)

33.626.723.823.5

Equity ratio (%)

74.878.980.881.0

Current ratio (x)

———2.08

Quick ratio (%)

———145.1

Interest coverage (x)

———4.77

Asset turnover (x)

———0.36

Receivables turnover (x)

———13.45

Inventory turnover (x)

———3.01

Revenue History

PeriodRevenue (KRW Bn)Operating income (KRW Bn)Net income (KRW Bn)Source

H1 FY2021

24.28.6—

Etoday, Aug 2021

H1 FY2024

22.55.41.5

Edaily, Aug 2024

9M FY2023

29.04.3—

Nongmin, Jan 2025

9M FY2024

32.16.85.0

Company release, Nov 2024

Q3 FY2024

9.61.3—

FnGuide

Q4 FY2024

1.8-4.5—

FnGuide (derived from FY less 9M)

Q1 FY2025

10.1–10.6

1.45—

FnGuide; KIND Q1 report

H1 FY2025

21.84.7—

Nongmin, Sep 2025

Revenue by Region

MetricFY2023FY2024FY2025

Total revenue (KRW Bn)

30.533.933.7

Market by Date

DateMarketProducts

Mar 2000

First exports (destination not disclosed)

—

Jun 2023

Thailand

Nargen, amino-acid products

Mar 2024

Japan

Organic materials, soil conditioners

Jun 2024

Mongolia

Organic materials

Aug 2024

Thailand (expansion)

Gel-formulation products, organic materials

Jan 2025

Japan (expansion)

Soil conditioners

May 2025

Kazakhstan

Test-bed support programme participation

Jan 2026

Egypt

Super Kelp

Feb 2026

Kazakhstan

Richen Fulvic

“—” = not publicly disclosed.

Share Price

MetricFY2018FY2022FY2023FY2025

Reference share price (KRW)

8,9005,4602,300500

Analyst Conclusions

Management guidance. No quantitative guidance. Qualitatively, management expects a return to revenue growth driven by eco-friendly organic materials, pesticide line extension, domestic subsidy programmes and exports (KIND Q1 FY2025; Edaily, Aug 2024).

Consensus. None (no coverage).

Bull case

  1. The operating franchise is intact and improving. OP recovered from KRW -0.5bn (FY2023) to KRW 2.8bn (FY2025), and net income turned positive (KRW 0.98bn) for the first time in at least four years. That occurred during suspension, delisting and litigation.

  2. Deep asset backing. Book equity of KRW 77.0bn with an 81% equity ratio. Land and buildings had a book value of KRW 36.3bn (Jun 2025). There is an Andiforce stake of about 18% plus a modern plant. The last observed market transactions (about KRW 900 per share) imply roughly 0.3x book.

  3. Strategic optionality. Two domestic sector players (Chobi and Kyungnong) have already paid to secure 18.24%, and Kyungnong previously bid for the parent. This creates a credible path to a consolidation exit that could crystallize synergies in distribution and R&D.

Bear case

  1. Growth is absent. Revenue CAGR is about 0% over FY2020–FY2025, the core domestic farm market is structurally challenged, and exports remain immaterial in disclosed figures.

  2. Governance discount may be permanent. KRX and a court found transparency deficits. The parent's ultimate ownership has been questioned, and minority holders lack an exchange exit. Value leakage through related-party transactions has precedent in the Andiforce purchase.

  3. Capital is poorly employed. ROE of about 1.3% on a large equity base, with non-core assets that have historically generated losses. Without disposals or distributions, minority shareholders may not capture asset value.

Key catalysts and monitorables (next 12 months)

  • FY2026 results and the H1 FY2026 margin trajectory, including whether the FY2025 OP recovery holds.

  • Verdict in Kim Woo-dong's criminal trial and any civil recovery by Daeyu.

  • Appeal outcome in the delisting-nullity litigation (low probability of relisting).

  • Any disposal of the Andiforce stake or of Seoul real estate.

  • Moves by Chobi and Kyungnong: further accumulation, litigation, or a negotiated transaction with Jogwang ILI.

  • Changes in Jogwang ILI's ownership (the JS Innovation Partners–Alpenroute fund; Dong Jin International).

  • Export traction in Egypt and Kazakhstan, and whether any export revenue is disclosed.

  • Raw-material cost pass-through amid 2026 geopolitical volatility.

  • Dividend policy, given minority-holder pressure for distributions.

Concluding analyst verdict.

Daeyu is a case study in how a sound, modest operating business can be overwhelmed by its capital structure and governance. The core franchise is real. Nargen and its sister lines have been sold for nearly five decades, gross margins run near 49%, and the company kept generating operating profit and positive operating cash flow through two years of suspension and a contested delisting. FY2025's return to net profit, on flat revenue of KRW 33.7bn, suggests the drag from non-operating investments has largely run its course, and the balance sheet is now conservative.

The structural problem is not leverage but stewardship. From 2020 the company was embedded in a chain of cross-holdings through Jogwang ILI and Andiforce. Capital raised from the public in 2022 coincided with the period in which non-core exposures generated roughly KRW 48bn of cumulative net losses. Both the exchange and the court concluded that transparency had not been restored. Delisting has removed the main external discipline on management just as a competitor bloc and a minority alliance remain inside the shareholder base. For minority holders, the investment case now depends almost entirely on a corporate event, such as a sale to a strategic buyer, a disposal of non-core assets, or a meaningful distribution policy, rather than on operating growth, which has been absent for six years.

On a standalone basis, Daeyu should be viewed as a stable but low-growth, low-return specialty formulator worth well above its last traded price on an asset basis. That value is not readily accessible because the controlling shareholder's interests may not align with those of minority holders. Positive monitorables are export disclosure, Andiforce monetization and dividends. Negative signals would be further related-party dealings or renewed leadership churn. The overall assessment is a sound operating asset inside an impaired governance structure, best approached as special-situations exposure rather than an operating-growth thesis.


APPENDIX A — DATA GAPS (NOT PUBLICLY DISCLOSED IN SOURCES REVIEWED)

  • Auditor; executive compensation; board committee structure; chair identity.

  • R&D expense; total patent count.

  • EBITDA; depreciation; capex; cash balance; debt maturity profile; EPS and DPS history.

  • Revenue by geography and export revenue.

  • Segment-level revenue in KRW by product category.

  • Final IPO price.

  • Current status of the Gyeongsan and Jincheon sites.

  • Appeal status in the delisting suit.

  • Verdict in the former CEO's criminal trial.

  • Scope of the 2025–2026 MOUs (Central Bio, T-Chem, The Gyun).

APPENDIX B — PRINCIPAL SOURCES

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackgroundSource

Nam Eul-jin (남을진)

CEO

Mar 2026 to present

Also CEO of parent Jogwang ILI (succeeded Hong Gi-heung there in 2025). Prior roles, education and age not disclosed.

NICE via Jobkorea and Saramin

Jo Sin-hwan (조신환)

Inside director

Elected 15 Oct 2025 EGM

—

Dealsite TV, Oct 2025

Seo Jang-ho (서장호)

Outside director

Appointed Dec 2024

Director, Cham Accounting Corporation

iNews24, Jan 2025

Lee Young-seok (이영석)

Outside director

Appointed Dec 2024

Representative judicial scrivener, Minwoo office

iNews24, Jan 2025

Statutory auditor (name not disclosed)

Auditor

—

The company stated in Oct 2025 that an auditor was already in office

Dealsite TV, Oct 2025

“—” = not publicly disclosed.

Board & Management Changes

PeriodCEO(s)Context

Mar 2014 – Jun 2015

Kwon Ok-sul

Founding-family era

Jun 2015 – Sep 2020

Kwon Sung-han

Led the 2018 IPO; sold control to Jogwang ILI in 2020

Sep 2020 – Mar 2023

Kim Woo-dong

Cornell economics graduate; formerly at Merrill Lynch and Liberty PE (Wonyesanup, Sep 2020). Arrested Apr 2023.

Mar 2023 – Sep 2023

Kim Woo-dong and Kim Cheol-han (co-CEOs)

Crisis period

Sep 2023 – Dec 2024

Jeong Chi-hun

Improvement-period management

Dec 2024 – Mar 2026

Lee Beop-jong

Appointed with full board refresh before the final KRX review

Mar 2026 to present

Nam Eul-jin

Concurrent with the Jogwang ILI CEO role

Major Shareholders

HolderStakeAs ofSource

Jogwang ILI Co., Ltd.

about 47.97%

Oct 2025

Agrinet; Newsfm

Chobi Co., Ltd. (KOSPI: 001550)

9.67%

Aug 2025

DigitalToday; Hankyung MI

Kyungnong Corp. (KOSPI: 002100)

8.02%

Aug 2025

DigitalToday

Chobi/Kyungnong related persons (Lee Seung-yeon, Lee Yong-jin, Lee Byung-man)

0.55%

Aug 2025

Agrinet

Minority Shareholders' Alliance (via ACT platform)

26.5% per Agrinet, or about 15% per the company's register count

Oct 2025

Agrinet; Greened

Other public holders

Remainder

Oct 2025

Derived

Competitive Landscape

Market Share by Competitor

CompetitorSegment overlapFY2025 revenueMarket share / positionNotesSource

Namhae Chemical (남해화학)

Fertilizers (commodity and compound)

—

Ranked 1st by NICE

Large-scale producer

Jobkorea ranking

Pungnong (풍농)

Compound fertilizers

—

Ranked 2nd

—

Jobkorea ranking

Chobi (조비, KOSPI 001550)

Compound and slow-release fertilizers

KRW 99.7bn (OP KRW 3.8bn)

About 9.4–9.7% of the national fertilizer market

Now an 18.24% Daeyu holder with Kyungnong

Butler.works; Valueline; Asia Economy

Nuvo (누보, KOSDAQ 332290)

Controlled-release coated, effervescent and functional fertilizers; crop protection; golf-course turf

KRW 104.2bn (OP KRW 4.1bn)

Ranked 4th

Strong in coated CRF technology

Butler.works; Jobkorea

Seoul Bio (서울바이오)

Microbial and organic materials

—

Ranked 5th

—

Jobkorea ranking

Segi (세기)

Fertilizers

—

Ranked 6th

—

Jobkorea ranking

Korea Agro (코리아아그로)

Fertilizers

—

Ranked 9th

—

Jobkorea ranking

Dongsin (동신)

Fertilizers

—

Ranked 10th

—

Jobkorea ranking

Jeju Fertilizer (제주비료)

Fertilizers

—

Ranked 11th

—

Jobkorea ranking

Kyungnong (경농, KOSPI 002100)

Crop protection (more than 95% of standalone revenue); fertilizers via subsidiary Chobi

KRW 232.3bn (+8.5%)

Major domestic crop-protection player

Parent of Chobi

Catch.co.kr; Valueline

Nongwoo Bio (농우바이오)

Seeds, plus growing media, fertilizers and pesticides

—

KOSDAQ-listed total agri-input player

—

Korea IR Council report

Peer Comparison FY2025

MetricDaeyuChobiNuvoKyungnong

Revenue (KRW Bn)

33.799.7104.2232.3

Revenue growth (%)

-0.8-2.65.28.5

Operating income (KRW Bn)

2.83.84.1—

Operating margin (%)

8.43.83.9—

Company Snapshot

$23.7M

Revenue

161

Employees

1977

Founded

SWOT Analysis

Strengths

  • Heritage brand. Nargen was launched in 1978 as Korea's first foliar Class-4 compound fertilizer and is still a core revenue line in 2026 (NICE).
  • High gross margin. FY2025 gross profit of KRW 16.4bn on KRW 33.7bn revenue is about 48.7% (NICE via Jobkorea).
  • Conservative balance sheet. Equity ratio of 81.0%, current ratio of 2.08x, and liabilities down from KRW 35.8bn (FY2022) to KRW 18.1bn (FY2025).
  • Positive operating cash generation. FY2025 operating cash flow was KRW 6.3bn, more than twice operating income (NICE).
  • Regulatory and testing capabilities. Multiple RDA-designated test institutions (pesticide efficacy 1999, microbial pesticides 2000, physicochemical analysis 2004, fertilizer 2008, organic materials 2013) and a GAP certification body designation (2009).
  • Modern capacity. The Goesan Smart Campus (site about 34,300 m²; completed 2022; full operation 2024) is credited with cost and efficiency gains (Edaily, Aug 2024).
  • Operating resilience during the crisis. FY2024 revenue rose 11.1% and FY2025 OP rose 26.6% while the company was suspended or delisted.

Weaknesses

  • Revenue stagnation. FY2020 revenue was KRW 33.6bn and FY2025 was KRW 33.7bn, roughly 0% CAGR over five years (FnGuide; NICE).
  • Value-destructive non-core investments. Cumulative net losses of about KRW 47.7bn in FY2022–FY2024 against positive OP in FY2022 and FY2024. The Andiforce partnership purchase was alleged to have caused about KRW 2bn of loss at indictment (Hankyung, Jan 2026).
  • Low returns on capital. FY2025 ROE was about 1.3% and ROIC about 1.04% (NICE).
  • Heavy opex load. About KRW 13.6bn of SG&A and other operating expense against KRW 16.4bn gross profit in FY2025.
  • Extreme seasonality. Q4 FY2024 revenue was KRW 1.8bn with a KRW 4.5bn operating loss (FnGuide).
  • Governance credibility deficit. Delisted after KRX found governance transparency insufficient. The court upheld that finding in January 2026 (Hankyung).
  • Leadership instability. Six CEO configurations between 2020 and 2026 (NICE).

Opportunities

  • Eco-friendly substitution. Management expects organic-material consumption to rise as pesticide use declines (KIND, Nov 2024; Q1 FY2025).
  • Export diversification. Entries into Thailand (2023), Japan and Mongolia (2024), Kazakhstan (2025–2026) and Egypt (2026) (company history).
  • Botanical pest management and biostimulants. Neem-based products (2025) and seaweed and fulvic products (2026).
  • Monetization of non-core assets. The Andiforce stake (about 18%) and Seoul HQ real estate. PP&E land and buildings had a book value of KRW 36.3bn at June 2025 (Hankyung MI).
  • Strategic interest from peers. Chobi and Kyungnong paid KRW 3.98bn for 18.24% and have shown interest in Daeyu (Hankyung MI, Aug 2025; Greened, Oct 2025). This raises the possibility of a future consolidation transaction.
  • Utilization upside at Goesan as volumes grow, given the plant was sized as the industry's largest facility investment (NICE 2021).

Threats

  • Ongoing legal overhang. Kim Woo-dong's criminal trial was ongoing as of early 2026, and no verdict was found in sources reviewed (Numbers; Law Times).
  • Minority-holder conflict. A competitor-held 18.24% block plus a minority alliance (reported at 15–26.5%) produced multiple lawsuits in 2025 (Greened; Livesnews).
  • Raw-material and geopolitical shocks. 2026 Hormuz-related fertilizer price spikes (Asia Economy references).
  • Weather and disaster risk. 2025 wildfires were cited as a demand drag (KIND Q1 FY2025).
  • Competitive intensity. Cited as a cause of the FY2023 revenue decline (KIND, Nov 2024).
  • Restricted capital-markets access. No equity market after delisting, and earlier CB financing triggered default mechanics in 2023 (Dealsite).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Daeyu and Jogwang ILI file main lawsuits against KRX to nullify the delisting decision Hankyung, Jan 2026Legal challenge to the delisting
22 Apr 2025Report that Daeyu plans further transparency steps at the parent, including Dong Jin International buying additional partnership interests from Paratek The Bell / Money TodayAttempt to address KRX's governance concerns
May 2025Participation in the Kazakhstan test-bed export support programme Company historyCentral Asian expansion
15 May 2025Q1 FY2025 report: gross profit KRW 5.01bn (vs 5.13bn); OP KRW 1.45bn (vs 2.03bn); 27.4% of sales via NongHyup and 72.5% via retailers KINDSofter start to the year
Late May 2025Prosecutors amend the indictment, cutting the alleged breach-of-trust loss at Daeyu and Jogwang ILI to about KRW 0.14–0.16bn each (sources differ on which amount applies to which company) Hankyung, Jan 2026; TTL NewsWeakened the original trigger for the listing review
Jul 2025ISO 9001, 14001 and 45001 certifications obtained; participation in the K-AgroEX export fair Company history; NICEQuality, environmental and safety systems
7 Aug 2025Seoul Southern District Court dismisses the injunction against delisting Nongmin, Sep 2025Delisting path cleared
11 Aug 2025Liquidation trading opens; aggregator shows a price of KRW 500 against the last pre-suspension price of KRW 2,300 Investing.comAbout 78% markdown versus the halt price
12–20 Aug 2025Chobi and Kyungnong accumulate 18.24% for KRW 3.98bn DigitalToday; Hankyung MICompetitor stake; potential takeover interest
Aug 2025Jogwang ILI raises its stake to about 48% during liquidation trading Newsfm; AgrinetControl consolidation
Mid-Aug 2025H1 FY2025 results: revenue KRW 21.8bn, OP KRW 4.7bn (vs 22.5bn and 5.4bn) Nongmin, Sep 2025Stable operations despite turmoil
21 Aug 2025Daeyu and Jogwang ILI delisted from KOSDAQ; Chobi files its 18.24% disclosure Nongmin; Hankyung MIEnd of public listing
3 Sep 2025The head of the ACT platform publicly criticizes Daeyu's shareholder-meeting conduct at a National Assembly forum Newsfm, Oct 2025Reputational and governance pressure
Sep 2025Chobi changes its stated holding purpose to management participation Greened, Oct 2025Escalation of the control contest
Sep 2025Company states that production and distribution are unaffected by delisting Nongmin, Sep 2025Commercial continuity
Pre-Oct 2025Court rejects Chobi's suit to restrict Jogwang ILI's voting rights and an injunction against agenda items Greened; Dealsite TVLegal wins for incumbent management
15 Oct 2025First post-delisting EGM in Pangyo: Jo Sin-hwan elected inside director; shareholder nominees and proposals (chair non-confidence, director removal, additional auditor) all defeated Nongmin; Dealsite TVIncumbent control confirmed
17 Oct 2025Chobi and Kyungnong publicly protest the blocking of their auditor proposal NewsfmOngoing minority-holder tension
Late 2025Kim Woo-dong's criminal trial continues; defence witnesses testify Law Times (Oct 2025); Numbers (early 2026)Unresolved legal overhang
Nov 2025Daeyu-man YouTube channel passes 100,000 subscribers Company historyMarketing reach
FY2025 closeFY2025: revenue KRW 33.68bn (-0.8%); OP KRW 2.83bn (+26.6%); net income KRW 0.98bn (first profit since at least FY2021) NICE via JobkoreaReturn to net profitability
Jan 2026Egypt market entry with Super Kelp Company historyExport diversification
Jan 2026 (reported 27 Jan)Seoul Southern District Court rules for KRX in Daeyu's delisting-nullity suit, holding that the reduced breach amount did not invalidate a decision based on overall transparency and continuity Hankyung, Jan 2026Relisting via litigation unlikely; appeal status not disclosed
Feb 2026Kazakhstan market entry with Richen Fulvic Company historyExport
Mar 2026CEO change: Lee Beop-jong replaced by Nam Eul-jin (concurrent Jogwang ILI CEO) NICETighter parent integration
Apr 2026Participation in the BKF export consultation Company historyExport
1H 2026Middle East conflict and Hormuz disruption fears lift Korean fertilizer equities, including peers Chobi and Kyungnong Asia Economy headline referencesRaw-material cost and price-volatility context
May 2026Strategic MOU with The Gyun (더균) Company historyPartnership
30 Jun 2026Headcount of 161 employees JobkoreaWorkforce down from 185 at end-2025 per NICE

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Fertilizer & agro-materials segment revenue fell from KRW 36,300 Mn in FY2021 to KRW 33,700 Mn in FY2025.
Daeyu Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Fertilizer & agro-materials segment revenue36,30035,40030,50033,90033,700
Segment operating income6,4004,500-5002,2002,800

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.